Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Loving these bargains. They will not last, people will be panic chasing in $$$ land soon enough $BIXT
Loving these bargains. They will not last, people will be panic chasing in $$$ land soon enough $BIXT
$BIXT had three golden crosses already. Nice peeerdy Money green curve back up late today and the gap up covered
**Huge update on $BIXT just out. Also the First Lady of the USA has Covid, announced late yesterday.** BIXT is in the buying zone, and not many cheap shares left before this makes a huge run IMO.
https://www.linkedin.com/pulse/small-pharma-poised-find-next-wonder-drug-after-big-pharmas-sheikh/
Are you offering to pay have off the convertible notes? And fund BIXT the right way?
I recall disgruntled investors that were unhappy with Moderna's lack of a product and revenue before Covid, threatening the CEO with suits over dilution and cash burn with no product or revenue, when Covid came out of left field saved Moderna's asses. No I am not going to dig up the proof. Lets move on...
About 6 months ago the entire US Banking system nearly failed... Months later US nearly defaulted on its debt..
3-4 months ago the money maggots all said "covid is over, no one cares".
The FED is trying to kill inflation and investing (which is and has been killing funding for biotechs), and the FED does not care about collateral damage.
I tried to tell them Covid ain't over. Did they listen? No. They are waking back up now. And fast..
a 20% increased Covid death rate week to week is an eye opener.
Sad truth is some jerks only care about money.
I care about seeing the BIXT antiviral technology get funded, approved and available to improve millions of lives and save millions of lives.
It is the ethical thing to do.
In one of your earlier post you indicated that Moderna needed funds and weeks later they were funded. I was one of the early investors in Moderna, correction, Moderna had 500 million in the coffers before Covid became a thing, plus pipelines going through the roof, until they were funded by the Government for their Covid vaccine. If this company truly has the science, they should have a partner to payoff the toxic notes.
$BIXT had three golden crosses already. Nice peeerdy Money green curve back up late today and the gap up covered
**Huge update on $BIXT just out. Also the First Lady of the USA has Covid, announced late yesterday.** BIXT is in the buying zone, and not many cheap shares left before this makes a huge run IMO.
https://www.linkedin.com/pulse/small-pharma-poised-find-next-wonder-drug-after-big-pharmas-sheikh/
Please copy and paste this everywhere! Personally email friends and social influencers to get this important meghage out!
https://www.linkedin.com/pulse/small-pharma-poised-find-next-wonder-drug-after-big-pharmas-sheikh/
The news of Covid was in national news today folks. The First Lady of the USA tested Positive for Covid today. It is news, news wakes up peep world to buy Covid stocks early. BIXT as of about 10 days ago is the only new FDA IND approval and the only viable one targeting Long haul Covid, with a non toxic antiviral that eliminates (Per India trials) in 3 days with an IV that shows PCR negative in 3 days. Not 2 weeks, but 3 days!!!
Long haul covid cases caused by residual spikes or residual virus should be curable with the BIXT antiviral.
And that would be just this beginning for this new new non toxic class of antivirals. The flu (also a corona virus) would targeted next. Mutations of the viruses would not get around the BIXT antiviral(s) because of how they work.
For the math challenged folks, it is simple. Do you buy now in volume at .21 or wait to buy the same company shares at .38 or .50 later this week?
This Nasdaq stock, $Prds, has $$$$$$ and no tech now and needs to desperately fund something like $BIXT IMO, to save themselves.
https://seekingalpha.com/article/4605537-pardes-bioscience-seeking-strategic-alternatives
Last call for BIXT bargains 2.0
If I was any one of several big pharma firms, I would be dangling a $100 Mil dollar JV and marketing deal at BIXT management right now.
Early bird gets the worm.
Indeed it can, in fact, BIXT just may turn out to be the David to the Moderna Goliath...
I recall early 2020, before Covid19, Moderna looked like it was in serious funding trouble, with no product revenue yet.
That Changed in weeks in 2020.
This could be JV deal coming with Big Pharma and a Buy out for 20 Billion dollars at some point. Wall Street Money is asleep at the wheel here, good for us buyers...
They will wake up because of this news, they just move slow, the ones that fund this kind of tech the right way..
Takes time. Some are like quietly eating shares, bid sitting and nibbling at the ask.
Great to see volume back up and climbing and a near 200% rally off the low, needed to cool off Friday. I Love more for less... These last shares will look like gifts shortly.
Covid is here to stay, just like the flue. The difference is that the Non toxic antiviral technology $BIXT has will have repeat sales to 9 Billion people year round, for every new wave of Covid and it can be adapted for the Flu and future corona viruses and strains. $BIXT tech is non toxic.
It can used as an oral pill for Covid (India trial is in the last part of the phase III trial already) and the US FDA IND is the first and only viable Long Haul Covid trial.
The India trial data is saying it will work for long haul covid, because it works for covid.
I called the Moderna buy in March 2020, before most people new Covid was going to be a problem based on the science.
Now here is the catch. Covid is so wide spread now, and mutates so fast, and it is jumping from Humans to deer, and Mink and back to humans, with massive new mutations they will never get rid of it with vaccines. And they can not make and test and distribute vaccines fast enough.
BIXT's antiviral works differently that the vaccines.
The Vaccines do not block cell infection.
The BIXT non toxic antiviral drug blocks the Covid / corona spikes so they can not infect human cells.
So no matter how many mutations the Covid comes up with the BIXT will still block off the spikes and their ability to attach to and infect cells.
So Infected people, can take the pill or IV and be back at work on day 4.
The new waves, Covid mutations that evade the vaccines and natural immunity world wide will keep coming, so demand for the BIXT drug will be steady world wide.
The drug can also work on Other corona viruses like the flue. This is going to be the best thing since sliced bread.
Ask yourself common sense questions, I got into this a little while ago from 21-23 cents, still holding not much though, just 30,000 shares. I had Moderna at 17-18 right before covid hit 8000 shares long and was posting that stock was going to triple digit dollars and it did of course didn't hold to the top but sold between 30-35 dollars, one morning it was 500 dollars premarket, cause they had 50 plus pipeline and indications going through the roof. I asked myself this question, if these guys really have the science like some guy says they do, someone would come in and pay of all the toxic funders and aim to get them on Nasdaq where they could do quality direct offerings, 500,000 dollars from accredited institutional investment is not going to cut it. I am going to stay and see how India plays out for them. There is still dilution on this stock and it prevents it from going up. There is only one love story in the OTC.
How viable do you think Bioxytran will be after COVID abates? Just curious to see if this could also be a long term play(?)
On high watch for me but this one seems to be back on it's way down. Lovely.
$BIXT looks poised for a trip to $$ land folks.
They are the only FDA IND, approved drug trial for Long haul Covid, that "clears Covid in 3 days", and that is 100% non toxic.
Let that sink in people.
https://insiderfinancial.com/the-next-axcella-axla-squeeze-bioxytran-bixt/184558/
If it is true, this stock will even hit 10 dollars in the OTC, it will have similar run like ALP*P. No one wants to miss out on the next Moderna.
World Changing news on $BIXT for sure.........
Z
If this news truly has any merits to it, it will go viral and this could jump $4-5 range by Christmas.
$BIXT Major US FDA News. This can be the next Moderna, only way better, not a vaccine, and non toxic antiviral that blocks viruses from being able to attach to human cells and infect them. This is Nobel prize winnable Technology.
https://www.globenewswire.com/news-release/2023/08/24/2731222/0/en/Bioxytran-Announces-FDA-Clearance-of-its-IND-Application-for-ProLectin-M-in-Clinical-Trials.html
Z
Looks like $BIXT is taking off nicely...........
Z
Yes, and right now the BIXT stock should be making moves to trade in the dollar land per share.
They are already in part 2 of part III of a phase III trial in India testing the non toxic Galectin antiviral for Covid19 that is agnostic to the
Covid19 mutations (should work on all of them, on all Covid Sars mutations, past and future) and today announce an FDA approval of the
IND Investigational New Drug trial Approval in the US.
This should wake up the market and rally this to $4 IMO.
EcoMike: By 'HUGE' are you thinking, say, ten dollars per share--and if so, how long do you think it might take before the company gets there? This one looks like a thin trader which often means sudden spikes in both directions but I also like the fact that roughly 80% of the outstanding shares are tightly held...
By "HUGE" are you conjecturing a ten dollar PPS or thereabouts? And if so, what general timeline do you think it might be reached in? Don't worry; I am NOT taking your comments as investing advice...this is the OTC after all...
I totally sgree
Time to load the boat with BIXT folks, no only is it not getting any cheaper it is going way higher. Get in early, or miss the best deals
hopefully bottomed
I started buying more BIXT today. Bottom is in. The upside potential is huge
https://www.bioxytraninc.com/pipeline#prolectin-pipeline
https://www.bioxytraninc.com/degenerative-diseases
This could be the next Moderna in a few years, and become the new antiviral standard. Non toxic antivirals and other huge potential tech...
It's been crickets here for a while... will they ever start/finish their PIII trial?
This money should get clinical trials on schedule!
news Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
Press Release | https://www.otcmarkets.com/stock/BIXT/news?id=404047
$BIXT NEWS: Press Release- Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
Published: June 12, 2023 at 9:02 a.m. ET
BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which cause COVID-19 and other viral diseases, announced that it has entered into a common stock purchase agreement with TRITON FUNDS LP for $500,000. The proceeds will help kickstart the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing. TRITON FUNDS is the second institutional investor aligning its investment strategy with the lead institutional investor Walleye Capital, LLC which was founded in 2005 and now has $5 billion plus of assets under management.
The funding is sufficient to reach the next milestone of a submission of a Phase 3 regulatory trial in India for mild to moderate COVID-19. Bioxytran's Clinical Research Organization (CRO) has indicated that dosing in the 40-patient trial is expected to commence within the month now that the funding is in place.
"As a cornerstone of our investment portfolio, TRITON FUNDS has been meticulously and strategically trying to build a robust position in Bioxytran over the past year", said Axel Olson, Equity Analyst and Entrepreneur in Residence at TRITON FUNDS. "Our investment not only serves to solidify our cost basis but, more importantly, empowers Bioxytran with the necessary capital infusion to propel them towards their impending milestone."
He added, "Having observed the company's trajectory for well over a year, we've been profoundly inspired by the tenacity and resilience of the management team, who have navigated with aplomb amidst a challenging regulatory and financial terrain. We are firm believers in the transformational potential of Bioxytran's technological prowess, a promising beacon that could drastically alter the treatment landscape for viral diseases. This investment represents our steadfast confidence in Bioxytran's capacity to usher in a new era in medical science."
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drugs called Galectin Antagonists designed to neutralize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
About TRITON FUNDS
As the nation's premier student-managed fund, TRITON FUNDS empowers students with real-world experience in Venture Capital and Private Equity. Our millennial-driven, alternative investment strategies foster growth and transformation in promising industries. We champion a growth cycle that benefits students, investors, and the broader community. Discover more at www.tritonfunds.com.
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
Makes you want to buy more BIXT!
https://seekingalpha.com/article/4605537-pardes-bioscience-seeking-strategic-alternatives
Followers
|
46
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1250
|
Created
|
03/23/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |